Steven A. Pergam

Adjunct Professor, Epidemiology
Professor, Medicine - Allergy and Infectious Dis.



MD University of Nebraska, 1998
MPH Epidemiology, University of Washington, 2008



Fred Hutchinson Cancer Research Center
Box 358080
1100 Fairview Ave. N, E4-100
Seattle, WA 98109
View Website »


Dr. Pergam is an Infectious Diseases physician and researcher who received his MD from the University of Nebraska School of Medicine, his Infectious Diseases fellowship training at the University of Washington (UW), and his MPH from the UW School of Public Health. Dr. Pergam serves as the Medical Director of Infection Prevention at the Seattle Cancer Care Alliance (SCCA). Dr. Pergam focuses his research on the prevention and treatment of infections among immunocompromised patients, and has expertise in infection prevention and hospital epidemiology among cancer and transplant patients. He serves on numerous national committees, including the CDC’s Advisory Committee on Immunization Practices, and the National Comprehensive Cancer Network Committee on the Prevention and Treatment of Infections in Cancer. He also is an Associate Editor for BMC Infectious Diseases and Current Opinions in Infectious Diseases.

Research Interests

Dr. Pergam’s research interests involve hospital epidemiology, antimicrobial resistance, and infection prevention in immunosuppressed hosts. His research group focuses on infection prevention, resistant pathogens, antimicrobial stewardship, and on the development of novel prevention strategies for community and healthcare-associated infections in cancer and hematopoietic cell transplant patients. He has active research projects that evaluate vaccinations, water-borne pathogens, resistant bacteria, respiratory virus transmission, and fungal infections among immunocompromised hosts. He is interested in the interplay between the immune response, the microbiome, bacterial and viral infections in the respiratory and gastrointestinal systems, and their association with inflammatory complications (e.g. Graft-versus-host disease, mucositis).

Recent Publications (PubMed)

Lessons From the COVID-19 Pandemic: Updating Our Approach to Masking in Health Care Facilities.
(2023 Sep)
Ann Intern Med 176(9): 1266-1268
Chow EJ, Lynch JB, Zerr DM, Riedo FX, Fairchok M, Pergam SA, Baliga CS, Pauk J, Lewis J, Duchin JS

Association of Self-Reported COVID-19 Vaccination Status with COVID-19 Infection among Adult Long-Term Hematopoietic Cell Transplantation Survivors.
(2023 Sep)
Transplant Cell Ther 29(9): 584.e1-584.e9
Liang EC, Onstad LE, Carpenter P, Pergam SA, Flowers ME, Lee SJ, Liu C

Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer.
(2023 Jun)
Open Forum Infect Dis 10(6): ofad306
Liu C, Yoke LH, Bhattacharyya P, Cassaday RD, Cheng GS, Escobar ZK, Ghiuzeli C, McCulloch DJ, Pergam SA, Roychoudhury P, Tverdek F, Schiffer JT, Ford ES

Analysis of Antibiotic Exposure and Development of Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Cell Transplantation.
(2023 Jun 1)
JAMA Netw Open 6(6): e2317188
Rashidi A, Gao F, Fredricks DN, Pergam SA, Mielcarek M, Milano F, Sandmaier BM, Lee SJ

Antiviral Prescribing Among Patients at an Ambulatory Cancer Center With Laboratory-Confirmed Influenza.
(2023 May)
Open Forum Infect Dis 10(5): ofad254
Sorey W, Krantz EM, Morris J, Klaassen J, Sweet A, Tverdek F, Escobar ZK, McCulloch DJ, Pergam SA, Liu C

Show complete publication list